Cencora, Inc. (COR)
Cencora is a massive middleman in the healthcare world, moving medicines from manufacturers to hospitals, pharmacies, and clinics across the globe.
Is Cencora, Inc. a good stock for a UK beginner?
The honest version: Cencora is a massive middleman in the healthcare world, moving medicines from manufacturers to hospitals, pharmacies, and clinics across the globe.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Long-term growth in the aging population driving higher medicine usage.
Significant regulatory changes that squeeze distribution fees.
What does Cencora, Inc. do?
Think of Cencora as the logistics backbone of the pharmaceutical industry; they don't make the drugs, but they ensure they get to where they are needed safely and efficiently. It earns its keep by taking a small slice of the value of the vast amount of medicine it distributes. Watch how they protect their razor-thin profit margins while handling the complex, ever-changing demands of global healthcare supply chains.
On our factor screen it looks strongest on income and value, and weakest on quality.
- ✓Pays a dividend - about 0.8% a year
- ✓Growing - revenue up about 4% over the year
- !Thin profits - turns only about 1% of sales into profit
- !Carries a lot of debt - roughly 4.2x its equity
- ✓Strong return on shareholder money (ROE 107%)
- Essential role in the global healthcare supply chain
- Low beta suggests relative stability compared to the broader market
- Strong track record of managing massive logistics networks
- Quality screens low (30/100)
- Regulatory changes impacting drug distribution fees
- Potential for supply chain bottlenecks or disruptions
- Intense competition within the pharmaceutical wholesale industry
What do Cencora, Inc.'s numbers mean?
How much money does Cencora, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Cencora, Inc. pay a dividend?
Yes - Cencora, Inc. currently pays a dividend of about 0.8% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Cencora, Inc. report earnings, and how did recent quarters go?
Cencora, Inc. is next scheduled to report on about 2026-08-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-06 | $4.73 | $4.75 | In line |
| 2026-02-04 | $4.04 | $4.08 | In line |
| 2025-11-05 | $3.79 | $3.84 | Beat +1% |
| 2025-08-06 | $3.84 | $4.00 | Beat +4% |
| 2025-05-07 | $4.10 | $4.42 | Beat +8% |
| 2025-02-05 | $3.52 | $3.73 | Beat +6% |
Across the last 6 quarters here, Cencora, Inc. came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Cencora, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Cencora, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Essential role in the global healthcare supply chain
- Low beta suggests relative stability compared to the broader market
- Strong track record of managing massive logistics networks
- Extremely thin profit margins leave little room for error
- High reliance on large-scale contracts with major healthcare providers
- Limited control over the pricing of the products they distribute
- Regulatory changes impacting drug distribution fees
- Potential for supply chain bottlenecks or disruptions
- Intense competition within the pharmaceutical wholesale industry
The write-up's own warning lights — if these start happening, the case above changes.
- A major shift in how drugs are distributed, such as direct-to-patient models bypassing wholesalers
- Significant, sustained decline in global pharmaceutical spending
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.